New Market - April 1, 2022
InDex Pharmaceuticals prepares for commercialization of cobitolimod
InDex Pharmaceuticals Holding is planning for self-commercialization of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis, states the company. Read more: Hey there Peter Zerhouni, […]
Clinical Trials - November 26, 2021
InDex Pharmaceuticals enrols first patient in phase III study
InDex Pharmaceuticals Holding has announced that the first patient has been enrolled in the phase III study CONCLUDE. The study will evaluate the efficacy and safety of the TLR9 agonist cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis. “Given cobitolimod’s outstanding combination of efficacy and safety, the annual global […]
Pharma Business - August 25, 2021
InDex Pharmaceuticals receives FDA clearance
The U.S. Food and Drug Administration (FDA) has given clearance to start the company’s phase III clinical study CONCLUDE in the United States. The study will evaluate the efficacy and safety of the TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis. “The United States is the largest pharmaceutical market in […]
Business article - April 28, 2020
Hey there Peter Zerhouni, CEO, InDex Pharmaceuticals
InDex Pharmaceuticals recently announced conclusions from its CONDUCT study, evaluating their TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. Congratulations to the positive results from the CONDUCT study. What are the next steps and when can we expect additional results? “Thank you! Thanks to the strong and unambiguous results from the […]
Clinical Trials - February 20, 2020
In-depth analysis of InDex Pharmaceuticals’ CONDUCT study
InDex Pharmaceuticals has announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that the highest dose tested, which met the primary endpoint of the study, demonstrates an […]
Clinical Trials - August 29, 2019
InDex Pharmaceuticals study has met the primary endpoint
The company has announced positive results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint of clinical remission, demonstrating a superior efficacy of 15% (delta) in patients receiving the highest dose of cobitolimod compared to placebo. Cobitolimod was well […]
